Given that NOX4 expression is upregulated in lung fibroblasts isolated from IPF patients, and that the protective effects of setanaxib in human cell lines replicate those seen in NOX4 KO models, these data strengthen evidence suggesting that the benefits of setanaxib treatment seen in pre‐clinical models could potentially be translated to human patients, warranting further exploration in a clinical trial setting. The gene discussed is NOX4; the disease is idiopathic pulmonary fibrosis.